Table 3 The growth data of the hepatic remnant after SOAP and the short-term and long-term outcomes after the second-stage operation
Variable | Terminal FLRV (ml), % of the SLV | Growth rate (ml/day) | Time interval (days) | Growth range (%) | CCI | AFP* (ng/ml) | LOS* (days) | DFS (months) | OS (months), status |
|---|---|---|---|---|---|---|---|---|---|
Patient 1 | 550, 53.5% | 18.4 | 12 | 30.60 | 8.7 | 15.9 | 19 | 4 | 9.2, dead |
Patient 2 | 456, 41.9% | 20.6 | 8 | 46.20 | 8.7 | 18.1 | 9 | > 40.2 | 40.2, alive without disease |
Patient 3 | 531, 37.7% | 16.5 | 13 | 51.70 | 43.3 | 4.7 | 12 | 7 | 13.8, dead |
Patient 4 | 642, 49.0% | 10.9 | 15 | 25.60 | 8.7 | 8.5 | 26 | 3.6 | 9.5, dead |
Patient 5 | 715, 54.1% | 25.8 | 17 | 41.60 | 8.7 | 9.9 | 13 | 6.2 | 20.8, alive with disease |
Patient 6 | 581, 43.8% | 10.4 | 15 | 27.40 | 8.7 | 3.2 | 12 | > 13.3 | 13.3, alive without disease |
Patient 7 | 420, 37.8% | 9 | 18 | 37.70 | 27.6 | 289.2 | 22 | 2.2 | 14.5, dead |
Patient 8 | 516, 45.6% | 10.9 | 13 | 34.00 | 8.7 | 14.8 | 14 | 6.5 | 13.5, alive with disease |
Patient 9 | 498, 42.7% | 10 | 16 | 39.10 | 8.7 | 19.3 | 18 | > 10.5 | 10.5, alive without disease |